0001437749-23-013125.txt : 20230508
0001437749-23-013125.hdr.sgml : 20230508
20230508215337
ACCESSION NUMBER: 0001437749-23-013125
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230425
FILED AS OF DATE: 20230508
DATE AS OF CHANGE: 20230508
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Plooster Matthew R
CENTRAL INDEX KEY: 0001638364
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36913
FILM NUMBER: 23899726
MAIL ADDRESS:
STREET 1: 2656 CROSSPARK ROAD
STREET 2: SUITE 100
CITY: CORALVILLE
STATE: IA
ZIP: 52241
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ZEVRA THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001434647
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205894398
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1180 CELEBRATION BOULEVARD, SUITE 103
CITY: CELEBRATION
STATE: FL
ZIP: 34747
BUSINESS PHONE: (321) 939-3416
MAIL ADDRESS:
STREET 1: 1180 CELEBRATION BOULEVARD, SUITE 103
CITY: CELEBRATION
STATE: FL
ZIP: 34747
FORMER COMPANY:
FORMER CONFORMED NAME: KEMPHARM, INC
DATE OF NAME CHANGE: 20130530
FORMER COMPANY:
FORMER CONFORMED NAME: KEMPHARM INC
DATE OF NAME CHANGE: 20080507
4
1
rdgdoc.xml
FORM 4
X0407
4
2023-04-25
0001434647
ZEVRA THERAPEUTICS, INC.
ZVRA
0001638364
Plooster Matthew R
C/O ZEVRA THERAPEUTICS, INC.
1180 CELEBRATION BOULEVARD, SUITE 103
CELEBRATION
FL
34747
1
0
Stock Option (right to buy)
5.59
2023-04-25
4
A
0
49200
0
A
2033-04-24
Common Stock
49200
49200
D
The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, April 25, 2023.
This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's eighth amended and restated non-employee director compensation policy.
One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Matthew R. Plooster
2023-05-08